InsiderTrades

Form 4 for MRNA Moderna

Accepted 2026-09-14 16:25:21 ET · period of report 2026-09-10 · accession 0001682852-26-000174 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DT 2026-09-14 16:25 2026-09-10 MRNA Mock James M CFO M - OptEx $30.96 +19.8K 94.2K +27% +$614.1K
DMT 2026-09-14 16:25 2026-09-10 MRNA Mock James M CFO S - Sale+OE $134.49 -34.8K 59.4K -37% -$4.69M
DT 2026-09-14 16:25 2026-09-10 MRNA Mock James M CFO M - OptEx $0.00 -19.8K 43.6K -31% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-09-10 M A 19,836 $30.96 94,211 D — — (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026.
2 Common Common Stock 2026-09-10 S D 19,836 $134.49 74,375 D — — (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026.
3 Common Common Stock 2026-09-10 S D 15,000 $134.49 59,375 D — — (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026.
4 Derivative Stock Option (Right to Buy) 2026-09-10 M D 19,836 $0.00 43,642 D $30.96 · — to 2035-03-01 19,836 Common Stock (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026. (F2) 25% of this option vested and become exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.